MSD has confirmed that its
Atozet composite pack (ezetemibe
and atorvastatin) will be listed
on the Pharmaceutical Benefits
Scheme effective from 01 Dec.
The new composite pack
contains two tablets side by
side, in a calendar format which
simplifies administration with both
cholesterol lowering medications
packed together.
The company says this supports
compliance by helping patients on
dual therapy to remember to take
both tablets at the same time.
The Atozet composite pack also
results in cost savings for patients
who take both medications, with
a single PBS co-payment required
rather than two.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Nov 13
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.